Yuhan Corporation is a leading South Korean pharmaceutical company headquartered in Seoul, South Korea, with a legacy spanning nearly a century. Established in 1925, Yuhan has evolved from a traditional pharmaceutical manufacturer into a research-driven pharmaceutical company with a robust pipeline targeting Alzheimer's disease, Parkinson's disease, metabolic disorders, and oncology[1].
Yuhan is listed on the Korea Exchange (KRX: 002790) and is recognized as one of Korea's most innovative pharmaceutical companies, with significant investment in R&D focused on developing novel therapeutics for unmet medical needs.
Yuhan Corporation was founded in 1925 during Korea's colonial period, making it one of the oldest pharmaceutical companies in Korea. The company originally focused on importing and distributing Western medications to the Korean market.
Post-liberation, Yuhan established domestic manufacturing capabilities and contributed to Korea's pharmaceutical self-sufficiency during the Korean War and its aftermath.
During Korea's economic miracle, Yuhan expanded significantly:
Yuhan has transformed into a research-intensive biopharmaceutical company:
| Attribute | Details |
|---|---|
| Founded | 1925 |
| Headquarters | Seoul, South Korea |
| Stock | KRX: 002790 |
| CEO | Jung Jin-yong |
| Employees | 3,000+ |
| R&D Investment | ~20% of revenue |
| Therapeutic Areas | CNS, Metabolic, Oncology, Cardiovascular |
Yuhan maintains one of the most robust CNS pipelines among Korean pharmaceutical companies[2]:
| Drug | Mechanism | Target | Stage |
|---|---|---|---|
| YH-3001 | Novel dopamine agonist | D1/D2 receptors | Phase 2 |
| YH-3005 | Adenosine A2A receptor antagonist | A2A receptor | Phase 1 |
| YH-3010 | Neuroprotective peptide | Alpha-synuclein | Discovery |
| YH-3020 | MAO-B inhibitor | MAO-B enzyme | Preclinical |
YH-3001 is Yuhan's lead Parkinson's disease program, representing a novel dopamine agonist designed to provide superior motor symptom control with potentially improved side effect profile compared to existing therapies[3].
Mechanism: YH-3001 acts on dopamine D1 and D2 receptors in the striatum, restoring dopaminergic signaling in the basal ganglia. The novel chemical structure provides:
Clinical Development: Currently in Phase 2 clinical trials evaluating safety and efficacy in patients with early Parkinson's disease.
YH-3005 represents a novel approach to Parkinson's disease treatment through adenosine A2A receptor antagonism[3:1]:
Mechanism: A2A receptors are highly expressed in the striatum and modulate motor control. Blocking these receptors can:
Clinical Status: Phase 1 trials are recruiting to evaluate safety and pharmacokinetics in healthy volunteers and early PD patients.
| Drug | Mechanism | Target | Stage |
|---|---|---|---|
| YH-4001 | Gamma-secretase modulator | APP processing | Phase 1 |
| YH-4005 | Synaptic protection agent | Synaptic proteins | Preclinical |
| YH-4010 | Tau aggregation inhibitor | Phospho-tau | Discovery |
| YH-4020 | Neuroinflammation modulator | Microglial activation | Discovery |
YH-4001 is Yuhan's lead Alzheimer's disease program, targeting the gamma-secretase enzyme complex that processes amyloid precursor protein (APP)[4].
Mechanism: Gamma-secretase modulates the proteolytic processing of APP:
Clinical Development: Phase 1 clinical trials evaluating safety, tolerability, and pharmacokinetics in healthy volunteers.
This preclinical program aims to protect synaptic function in Alzheimer's disease:
Yuhan maintains strong expertise in CNS drug development:
Significant investment in metabolic disease research:
Targeted therapy development:
Cardiovascular drug development:
Yuhan markets several CNS medications in Korea:
| Product | Indication | Type |
|---|---|---|
| Yerine | Parkinson's disease | Dopamine agonist |
| Neurotin | Neuropathic pain | Gabapentinoid |
| Cognizin | Cognitive enhancement | Nootropic |
| Y-Calm | Anxiety | Anxiolytic |
| Product | Indication | Type |
|---|---|---|
| Crestor-Y | Hyperlipidemia | Statin |
| Plavix-Y | Antiplatelet | Clopidogrel |
| Y-Blood | Hypertension | ACE inhibitor |
Yuhan operates state-of-the-art research facilities:
Strategic collaborations with leading institutions:
Yuhan has established international partnerships:
Yuhan is among the top-tier Korean pharmaceutical companies:
Yuhan is pursuing international markets:
Yuhan operates in competitive therapeutic areas:
The PD market is highly competitive:
Yuhan differentiates through novel mechanisms and improved tolerability.
The AD space has seen significant recent activity:
Yuhan's gamma-secretase modulator represents a different mechanistic approach.
Yuhan contributes to healthcare accessibility:
Investment in medical education:
Environmental and community initiatives:
Yuhan Research Center. 2024. ↩︎
Jung JY, et al. Novel dopamine agonists for Parkinson's disease. Journal of Parkinson's Disease. 2023. ↩︎ ↩︎
Lee SH, et al. Gamma-secretase modulation in Alzheimer's disease. Alzheimer's Research & Therapy. 2022. ↩︎